INmune Bio announced on October 28, 2026, that it had agreed to sell 3 million shares to a healthcare-focused institutional investor, alongside warrants to purchase up to another 3 million shares. The INmune Bio offering is expected to raise approximately $4.50 million before fees and expenses.

Key Takeaways

  • The warrants have an exercise price of $1.65 per share and become exercisable six months after issuance.
  • The transaction is expected to close on or about October 29, subject to customary conditions.

INmune Bio offering terms

The biotechnology company entered a definitive agreement with a single investor for the registered direct share offering and concurrent private placement of unregistered warrants. The warrants expire five and a half years after issuance.

INmune Bio intends to use net proceeds for working capital. A.G.P./Alliance Global Partners is the sole placement agent.

Registration and closing

The shares are being offered under a shelf registration statement declared effective by the Securities and Exchange Commission on August 7, 2024. INmune Bio also identified that shelf registration statement in its September 2024 offering announcement.

The warrants and their underlying shares are being privately placed under an exemption from registration. The company agreed to file a registration statement covering resale of the underlying shares within 30 days after closing.

Next milestone

The next milestone is the expected closing on or about October 29, 2026, subject to customary conditions.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.